# Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

> **NCT05668962** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Thyroid Cancer
- Thyroid Carcinoma
- Metastatic Thyroid Cancer
- Follicular Thyroid Cancer
- Unresectable Thyroid Gland Carcinoma
- Papillary Thyroid Cancer

## Interventions

- **DRUG:** Selpercatinib
- **DRUG:** Sodium Iodine I-131
- **DRUG:** rhTSH

## Key facts

- **NCT ID:** NCT05668962
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668962, "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05668962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*